X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs CIPLA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS CIPLA IPCA LABS/
CIPLA
 
P/E (TTM) x 41.9 45.7 91.7% View Chart
P/BV x 3.2 3.9 82.1% View Chart
Dividend Yield % 0.2 0.3 48.8%  

Financials

 IPCA LABS   CIPLA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
CIPLA
Mar-17
IPCA LABS/
CIPLA
5-Yr Chart
Click to enlarge
High Rs643622 103.4%   
Low Rs503458 109.7%   
Sales per share (Unadj.) Rs254.4181.9 139.9%  
Earnings per share (Unadj.) Rs16.112.9 124.9%  
Cash flow per share (Unadj.) Rs29.829.3 101.6%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.4 47.1%  
Book value per share (Unadj.) Rs194.6155.7 125.0%  
Shares outstanding (eoy) m126.20804.51 15.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.33.0 75.8%   
Avg P/E ratio x35.742.0 85.0%  
P/CF ratio (eoy) x19.218.4 104.4%  
Price / Book Value ratio x2.93.5 84.9%  
Dividend payout %6.215.5 40.0%   
Avg Mkt Cap Rs m72,300434,516 16.6%   
No. of employees `00013.323.0 57.7%   
Total wages/salary Rs m6,96026,338 26.4%   
Avg. sales/employee Rs Th2,413.56,349.1 38.0%   
Avg. wages/employee Rs Th523.21,143.0 45.8%   
Avg. net profit/employee Rs Th152.4449.3 33.9%   
INCOME DATA
Net Sales Rs m32,106146,302 21.9%  
Other income Rs m2262,287 9.9%   
Total revenues Rs m32,332148,589 21.8%   
Gross profit Rs m4,44824,758 18.0%  
Depreciation Rs m1,73013,229 13.1%   
Interest Rs m2411,594 15.1%   
Profit before tax Rs m2,70312,222 22.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6751,798 37.6%   
Profit after tax Rs m2,02810,354 19.6%  
Gross profit margin %13.916.9 81.9%  
Effective tax rate %25.014.7 169.8%   
Net profit margin %6.37.1 89.3%  
BALANCE SHEET DATA
Current assets Rs m17,34087,370 19.8%   
Current liabilities Rs m9,55933,081 28.9%   
Net working cap to sales %24.237.1 65.3%  
Current ratio x1.82.6 68.7%  
Inventory Days Days10087 115.3%  
Debtors Days Days5762 91.3%  
Net fixed assets Rs m20,779111,567 18.6%   
Share capital Rs m2521,609 15.7%   
"Free" reserves Rs m24,499123,645 19.8%   
Net worth Rs m24,553125,254 19.6%   
Long term debt Rs m3,51736,454 9.6%   
Total assets Rs m39,595209,532 18.9%  
Interest coverage x12.28.7 141.0%   
Debt to equity ratio x0.10.3 49.2%  
Sales to assets ratio x0.80.7 116.1%   
Return on assets %5.75.7 100.5%  
Return on equity %8.38.3 99.9%  
Return on capital %10.58.5 123.4%  
Exports to sales %48.634.2 142.2%   
Imports to sales %14.28.3 170.7%   
Exports (fob) Rs m15,61750,050 31.2%   
Imports (cif) Rs m4,57112,203 37.5%   
Fx inflow Rs m15,61751,066 30.6%   
Fx outflow Rs m5,82817,678 33.0%   
Net fx Rs m9,79033,388 29.3%   
CASH FLOW
From Operations Rs m2,76423,824 11.6%  
From Investments Rs m-1,432-13,127 10.9%  
From Financial Activity Rs m-1,591-13,239 12.0%  
Net Cashflow Rs m-259-2,478 10.4%  

Share Holding

Indian Promoters % 45.9 16.0 286.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 11.4 12.2 93.4%  
FIIs % 25.3 23.7 106.8%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.4 26.2 66.4%  
Shareholders   36,892 161,166 22.9%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PANACEA BIOTECH  DISHMAN PHARMA  TTK HEALTHCARE  NATCO PHARMA  BIOCON LTD  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 16, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS